EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities

Sumana Vardhan, Clare Arnott, Angela Xun-Nan Chen, Antonina Frolova, Raina Meka, Nandini Raghuraman, Aishwarya Vijay, Sang Gune Yoo, Zainab Mahmoud

American Journal of Preventive Cardiology · 2026-06 · 27 · 101471

DOI: 10.1016/j.ajpc.2026.101471 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Preventive Cardiology, 2026-06. Verfasst von Sumana Vardhan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Cardiovascular disease (CVD) is a leading cause of maternal mortality. Adverse pregnancy outcomes (APOs), including preeclampsia and gestational diabetes, confer significant long-term cardiometabolic risk, yet prevention strategies during the preconception and postpartum periods are limited. Glucagon-like-peptide 1 receptor agonists and/or combined therapies (GLP-1 agonists) have demonstrated substantial benefits in weight reduction, glycemic and lipid control, and cardiovascular risk reduction in nonpregnant populations, but their impact on cardiometabolic health in women with increased risk of CVD during peripartum phases has not been defined. Content: GLP-1 agonists are not approved for use during pregnancy or lactation; however, emerging evidence suggest a potential role in preconception weight optimization and postpartum metabolic recovery. This review highlights the mechanisms of GLP-1 agonists, evaluates available safety and efficacy data relevant to reproductive-age populations, and examines the potential application GLP-1 agonists during the preconception and postpartum periods, while also highlighting current clinical uncertainties. Summary: GLP-1 agonists represent a promising preventive strategy for cardiometabolic risk reduction in women with increased risk of CVD. However, data specific to reproductive-age populations remain limited, leaving critical gaps regarding safety, efficacy, optimal timing of use, and implementation. Recognizing the preconception and postpartum periods as pivotal windows for CVD prevention underscores the need for focused research to guide evidence-based integration of effective interventions into preventative cardiovascular care for women.

Autor:innen und Institutionen

  • Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.
  • Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, University of Sydney, Sydney, Australia.
  • Department of Cardiology, St. Vincent's Hospital, Sydney, Australia.
  • Department of Diabetes & Endocrinology, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.
  • Department of Obstetrics and Gynecology, Washington University School of Medicine in St. Louis, MO, USA.

Förderung

  • National Institutes of Health

Zitieren

APA

Vardhan, S., Arnott, C., Chen, A. X., Frolova, A., Meka, R., Raghuraman, N., Vijay, A., Yoo, S. G., & Mahmoud, Z. (2026). Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities. American Journal of Preventive Cardiology, 27, 101471. https://doi.org/10.1016/j.ajpc.2026.101471

Vancouver

Vardhan S, Arnott C, Chen AX, Frolova A, Meka R, Raghuraman N, et al. Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities. American Journal of Preventive Cardiology. 2026;27:101471. doi:10.1016/j.ajpc.2026.101471

BibTeX
@article{Vardhan2026,
  author = {Vardhan, Sumana and Arnott, Clare and Chen, Angela Xun-Nan and Frolova, Antonina and Meka, Raina and Raghuraman, Nandini and Vijay, Aishwarya and Yoo, Sang Gune and Mahmoud, Zainab},
  title = {Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities},
  journal = {American Journal of Preventive Cardiology},
  year = {2026},
  volume = {27},
  pages = {101471},
  doi = {10.1016/j.ajpc.2026.101471}
}
Kostenlos starten →